| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 08/27/2009 | US20090214422 DNA encoding a novel RG1 polypeptide |
| 08/27/2009 | US20090214420 Method of Diagnosis and Treatment and Agents Useful for Same |
| 08/27/2009 | DE202009007976U1 Neue Pharmazeutika und Arzneimittelzubereitungen, welche die Tumorzellproliferation und/oder Tumorvaskularisation hemmen, und ihre Wirkung als Multi-Kinase-Inhibitoren New pharmaceuticals and pharmaceutical compositions which inhibit tumor cell proliferation and / or tumor vascularization, and its effect as a multi-kinase inhibitors |
| 08/27/2009 | CA2844188A1 Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereof |
| 08/27/2009 | CA2716321A1 Methods for treating cancer using combination therapy |
| 08/27/2009 | CA2716288A1 Copper-organic complexes, use thereof as antitumor agents and for protecting healthy tissue from ionizing radiation |
| 08/27/2009 | CA2716019A1 Antitumoral agents with a benzophenanthridine structure and formulations containing them |
| 08/27/2009 | CA2716015A1 Kinase protein binding inhibitors |
| 08/27/2009 | CA2715885A1 Novel compounds and methods for therapy |
| 08/27/2009 | CA2715747A1 B ring reduced-d ring oxidized tetrapyrollic photosensitizers for photodynamic therapy and tumor imaging |
| 08/27/2009 | CA2715632A1 Synthetic scfv analogue to the 6313/g2 (anti angiotensin ii type 1 receptor) monoclonal antibody variable regions |
| 08/27/2009 | CA2715324A1 Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereof |
| 08/27/2009 | CA2715181A1 Combination therapy 238 |
| 08/27/2009 | CA2714700A1 Heterocyclic compounds and compositions as c-kit and pdgfr kinase inhibitors |
| 08/27/2009 | CA2714668A1 Compositions comprising phytoestrogens selective for estrogen beta receptor and dietary fibres |
| 08/27/2009 | CA2714608A1 Combination comprising paclitaxel for treating ovarian cancer |
| 08/27/2009 | CA2714215A1 Novel aminopyridine derivatives having aurora a selective inhibitory action |
| 08/27/2009 | CA2713872A1 Methods and compositions related to peptides and proteins with c-terminal elements |
| 08/26/2009 | EP2093294A1 Nucleotide and protein sequences of Nogo genes and methods based thereon |
| 08/26/2009 | EP2093293A2 G-Protein coupled receptors |
| 08/26/2009 | EP2093292A2 Inhibition of specific histone deacetylase isoforms |
| 08/26/2009 | EP2093237A1 Cancer therapeutic agent comprising anti-hb-egf antibody as active ingredient |
| 08/26/2009 | EP2093233A1 Novel compositions and methods in cancer |
| 08/26/2009 | EP2093228A1 Pyrroline-2-one derivatives against cell releasing tumor necrosis factor, preparation methods and uses thereof |
| 08/26/2009 | EP2093214A1 Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents |
| 08/26/2009 | EP2092938A1 Survivin-derived peptides and use thereof |
| 08/26/2009 | EP2092913A1 Implantable stent prothesis |
| 08/26/2009 | EP2092058A1 Cancerous disease modifying antibodies |
| 08/26/2009 | EP2091972A1 Multi-modal cancer therapy using viral hitch-hiking |
| 08/26/2009 | EP2091967A1 Crystalline composition of gm-csf/gm-csfr |
| 08/26/2009 | EP2091965A1 Peptide vaccines for cancers expressing mphosph1 or depdc1 polypeptides |
| 08/26/2009 | EP2091941A2 Mapk/erk kinase inhibitors |
| 08/26/2009 | EP2091926A1 Substituted pyrazole and triazole compounds as ksp inhibitors |
| 08/26/2009 | EP2091925A1 Bicyclic heterocycles, medicaments containing said compounds, use thereof, and method for production of same |
| 08/26/2009 | EP2091920A2 Substituted pyrazoles, compositions containing these, method of production and use |
| 08/26/2009 | EP2091919A1 Derivatives of 18-amino substituted analogs of the geldamycin hydroquinon with cytotoxic activity for the treatment of cancer |
| 08/26/2009 | EP2091611A2 New drug for treating gastric cancer |
| 08/26/2009 | EP2091565A2 Method of diagnosing and treating glioma |
| 08/26/2009 | EP2091547A2 Composition for the treatment of gastrointestinal diseases |
| 08/26/2009 | EP2091544A2 Composition for the prevention and/or treatment of diseases associated with tnf and/or il-12 overexpression |
| 08/26/2009 | EP2091532A1 Use of indolyl-3-glyoxylic acid derivatives including indibulin, alone or in combination with further agents for treating cancer |
| 08/26/2009 | EP2091336A2 Formulations comprising extracts from primitive plant species (mosses, ferns and lichens) to treat and prevent cancers |
| 08/26/2009 | EP2091329A1 Indazole compounds |
| 08/26/2009 | EP1981878B1 Indazole heteroaryl derivatives |
| 08/26/2009 | EP1858898B1 Hydrazinocarbonyl-thieno[2,3-c]pyrazoles, preparation method, compositions containing same and use |
| 08/26/2009 | EP1773817B1 Substituted aryl-amine derivatives and methods of use |
| 08/26/2009 | EP1648481B1 Viral vectors |
| 08/26/2009 | EP1601694B1 Uses of il-23 antagonists; related reagents |
| 08/26/2009 | EP1561759B9 Cell death-inducing agent |
| 08/26/2009 | EP1530584B1 Synthetic or natural peptides binding protein phosphatase 2a, identification method and uses |
| 08/26/2009 | EP1485087B1 (+)-2- [1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione for use in treating psoriasis by oral administration |
| 08/26/2009 | EP1423428B1 Antibodies that block fgfr3 activation, methods of screening for and uses thereof |
| 08/26/2009 | EP1328279B1 Compositions comprising lignin and methods of making and using the same |
| 08/26/2009 | EP1299524B1 Human myeloma cell line |
| 08/26/2009 | EP1296714B1 Combination of CpG and antibodies directed against CD19,CD20, CD22 or CD40 for the treatment or prevention of cancer. |
| 08/26/2009 | EP1237915B1 Polynucleotid encoding the rg1 polypeptide |
| 08/26/2009 | EP1218375B1 Pharmaceutically active sulfonyl amino acid derivatives |
| 08/26/2009 | EP1173441B1 6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations |
| 08/26/2009 | EP1061812B1 Food products having enhanced cocoa polyphenol content and processes for producing same |
| 08/26/2009 | EP1012187B1 Chemokine peptides, variants, derivatives and analogs. their use in methods to inhibit or augment an inflammatory response |
| 08/26/2009 | CN101517075A Cell death inducer |
| 08/26/2009 | CN101516904A Dimeric IAP antagonists |
| 08/26/2009 | CN101516891A Dihydrothieno pyrimidines as AKT protein kinase inhibitors |
| 08/26/2009 | CN101516888A Pyrazolo [1, 5-a] pyrimidine derivatives and their therapeutic use |
| 08/26/2009 | CN101516883A Imidazopyrazines as protein kinase inhibitors |
| 08/26/2009 | CN101516882A Selective antagonists of A2A adenosine receptors |
| 08/26/2009 | CN101516881A 2-aryl-6-phenylimidazo[1,2-a]pyridine derivatives, preparation thereof and therapeutic use thereof |
| 08/26/2009 | CN101516870A Salts of benzimidazolyl pyridyl ethers and formulations thereof |
| 08/26/2009 | CN101516850A Heteroaryl compounds useful as inhibitors of E1 activating enzymes |
| 08/26/2009 | CN101516406A Method of optimizing the treatment of Philadelphia-positive leukemia with Abl tyrosine kinase inhibitors |
| 08/26/2009 | CN101516385A Treatment of excessive neovascularization |
| 08/26/2009 | CN101516384A Anti-tumoral, antibacterial and antiviral pharmaceutical composition (variants) |
| 08/26/2009 | CN101516377A New medical use of triazine derivatives |
| 08/26/2009 | CN101516376A Method for treating cancer harboring EGFR mutations |
| 08/26/2009 | CN101516375A Combinations of class-I specific histone deacetylase inhibitors with proteasome inhibitors |
| 08/26/2009 | CN101516374A Histone deacetylase inhibitors with combined activity on class-I and class-IIB histone deacetylases in combination with proteasome inhibitors |
| 08/26/2009 | CN101516344A Pharmaceutical compositions comprising nilotinib or its salt |
| 08/26/2009 | CN101514354A Sea cucumber polypeptide, preparation method and application thereof |
| 08/26/2009 | CN101514326A Oxytropis ehrig verticillium FEL5-AS1 of synthesized swainsonine and application thereof |
| 08/26/2009 | CN101514234A Blackfungus polyhexose extraction method |
| 08/26/2009 | CN101514230A Monoclone antibody of ARD1 and application thereof |
| 08/26/2009 | CN101514229A Human interferon alpha derivative and polyethylene glycol modified substance thereof |
| 08/26/2009 | CN101514228A N-terminal modified human thymosin alfa 1 compound and preparation method thereof |
| 08/26/2009 | CN101514222A Steroidal compound in Bugula neritina L. and use thereof |
| 08/26/2009 | CN101514192A Quinoxalinone derivative with activity for reversing tumor cell multidrug resistance and preparation method thereof |
| 08/26/2009 | CN101514189A Glycin diazole tromethamine compound as well as preparation method and medicament application thereof |
| 08/26/2009 | CN101514177A Method for extracting lutein from marigold particles |
| 08/26/2009 | CN101514174A Method for extracting multifunctional sulforaphane from broccoli sprouting vegetable |
| 08/26/2009 | CN101513532A application of hBexl gene in preparation of tumor cell multidrug resistance reversal agents |
| 08/26/2009 | CN101513530A Polyhydroxyalkanoate (PHA) targeted carrier, drug-loading nano-particle and preparation methods and application thereof |
| 08/26/2009 | CN101513528A Compound chemotherapy medicament for treating liver cancer and multi-drug resistance tumor |
| 08/26/2009 | CN101513526A Application of combined vaccine in treating tumors |
| 08/26/2009 | CN101513515A Chinese patent drug for treatment of lung cancer |
| 08/26/2009 | CN101513509A Medicament for relieving cancer symptoms and method for preparing same |
| 08/26/2009 | CN101513508A Chinese medicament for treating breast cancer, and preparation method thereof |
| 08/26/2009 | CN101513431A Omphalia preparation and preparation method |
| 08/26/2009 | CN101513408A Novel application of preparation of diguanidino-prine derivatives in improving drug effects of anti-cancer drugs |
| 08/26/2009 | CN101513407A Application of naloxone and composition thereof in preparing drug for treating cancer |
| 08/26/2009 | CN101513400A Ampelopsin and basic amino acid solubilizing system |
| 08/26/2009 | CN101513399A Application of T-2 toxin in the preparation of drugs for treating bone cancers and myeloproliferative disorder |